INZY NASDAQ
Inozyme Pharma, Inc.
1W: +0.2%
1M: +0.5%
3M: +359.8%
1Y: -10.3%
3Y: -22.5%
$4.00
Last traded 2025-07-02 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$258.2M
52W Range0.721-6.24
Volume1,459,443
Avg Volume2,209,767
Beta2.29
Dividend—
Analyst Ratings
Company Info
CEODouglas A. Treco
Employees67
SectorHealthcare
IndustryBiotechnology
IPO Date2020-07-24
Websiteinozyme.com
321 Summer Street
Boston, MA 02210
US
Boston, MA 02210
US
857 330 4340
About Inozyme Pharma, Inc.
Inozyme Pharma, Inc. operates as a biopharmaceutical entity dedicated to addressing rare diseases. Its primary mission involves pioneering treatments for disorders characterized by aberrant mineralization, which impacts the body's vascular system, soft tissues, and skeletal structure. The company's flagship therapeutic candidate, INZ-701, is an engineered, soluble protein under development to combat specific genetic conditions, namely ENPP1 and ABCC6 deficiencies, as well as for the management of calciphylaxis. Inozyme maintains a licensing arrangement with Yale University concerning particular therapeutic and preventative agents. Established in 2015, the firm's main offices are situated in Boston, Massachusetts.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Subramanian Sanjay | D-Return | 180,000 | $3.96 | 2025-07-01 |
| Subramanian Sanjay | D-Return | 135,000 | $3.30 | 2025-07-01 |
| Subramanian Sanjay | D-Return | 145,000 | $1.06 | 2025-07-01 |
| Subramanian Sanjay | U-Tender | 39,701 | $4.00 | 2025-07-01 |
| Subramanian Sanjay | D-Return | 38,500 | — | 2025-07-01 |